



DOCKET NO: 17243CIP3(AP)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chow et al.)
Serial No.: 09/815,362)
Filed: March 21, 2001)
For: COMPOUNDS AND METHOD OF)
TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE)
AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS)
Examiner: Floyd D. Higel)
Art Unit: 1626)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Petition to Correct Inventorship, Assistant Commissioner for Patents, Washington, D.C. 20231 on:

2/28/02
(Date of Deposit)

BONNIE FERGUSON
Printed Name of Person Making Deposit

Bonnie Ferguson
Signature

2/28/2002
Date of Signature

PETITION FOR CORRECTION OF INVENTORSHIP

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants hereby petition the Commissioner pursuant to 37 CFR 1.48(a) to correct the inventorship in the above-referenced patent application. Through error, inventor Dario M. Gomez was not named as a joint inventor when this continuation patent application was filed. This error was made by the undersigned without deceptive intent in the haste to file the present application; such haste was exacerbated by the fact the undersigned was simultaneously working without an experienced assistant at the time, a lack that has thankfully since been cured.

Accordingly, Applicants petition the Commissioner to amend the application to set forth the actual inventors. Accompanying this petition is 1) a Statement of Dario M. Gomez in support of the correction of inventorship, 2) a Declaration by the actual inventors as required by 37 CFR §1.63, and 3) the written consent of the assignee, Allergan Sales, Inc., for such correction of inventorship.

11/03/2003 NVILLARI 00000012 09815362

01 FC:1460 130.00 DA